| Identification | Back Directory | [Name]
GATIFLOXACIN MESYLATE | [CAS]
316819-28-0 | [Synonyms]
AM 1155 mesylate
PD 135432 mesylate)
GATIFLOXACIN MESYLATE
BMS 206584-01 mesylate
GATIFLOXACIN MESYLATE USP/EP/BP
Gatifloxacin mesylate
(AM 1155 mesylate
AM 1155 MESYLATE;BMS 206584-01 MESYLATE;PD 135432 MESYLATE
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-(3-Methyl-1-piperazinyl)-4-oxo-, MonoMethanesulfonate (9CI) | [Molecular Formula]
C19H22FN3O4.CH4O3S | [MDL Number]
MFCD09954660 | [MOL File]
316819-28-0.mol | [Molecular Weight]
471.503 |
| Hazard Information | Back Directory | [Uses]
Gatifloxacin mesylate is a fourth generation fluoroquinolone antibiotic with broad-spectrum antibacterial activity. It is able to inhibit bacterial type II topoisomerase (IC50 = 13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA rotamase (IC50 = 0.109 μg/ml). It can be used to treat bacterial conjunctivitis in vivo, and its injection can treat acute urinary tract infections with efficacy comparable to levofloxacin hydrochloride injection[1]. | [References]
[1] L. DENG. Observation on the curative effect of gatifloxacin mesylate injection in the treatment of acute urinary tract infections[J]. 國際醫(yī)藥衛(wèi)生導(dǎo)報, 2009. DOI:10.3760/CMA.J.ISSN.1007-1245.2009.05.025. |
|
|